Bioassay based screening for the antiplatelet aggregation quality markers of Polygonum multiflorum with UPLC and chemometrics

Publication date: Available online 9 January 2019Source: Journal of Pharmaceutical and Biomedical AnalysisAuthor(s): Chunyu Li, Can Tu, Yi Che, Mingyu Zhang, Bin Dong, Xiaowei Zhou, Yafei Shi, Guohui Li, Jiabo WangAbstractCurrently, an increasing number of human’s health is seriously affected by acute thrombotic events. In China, Polygonum multiflorum (PM) is commonly used to treat diseases associated with thrombosis. Our previous work showed that PM could inhibit platelet aggregation that play a key role in the pathogenesis of thrombosis. However, the constituents of PM are complicated and its quality control methods cannot completely ensure the quality of PM related to clinical efficacy. Attempts to explore puzzles, we constructed a direct bioassay method to evaluate antiplatelet aggregation effects of PM. To ensure the precision and reliability of the bioassay, we optimized and standardized the experimental conditions of this method and then tested the standardized bioassay by analyzing 10 batches of PM. Additionally, we combined chemical evaluation with biological evaluation to identify its antiplatelet aggregation markers. The results showed that 10 samples of PM could inhibit platelet aggregation and there was a big difference in biopotency between different batches of PM. Chemical fingerprints revealed the variations in the contents of 7 main peaks. Trans-2,3,5,4’-tetrahydroxy-stilbene-2-O-β-D-glucoside and catechin might be the active constituents of antiplatelet...
Source: Journal of Pharmaceutical and Biomedical Analysis - Category: Drugs & Pharmacology Source Type: research